CirculationPub Date : 2026-11-03Epub Date: 2026-11-02DOI: 10.1161/CIRCULATIONAHA.126.081751
Alisa Morss Clyne, Elazer R Edelman
{"title":"From Custom Devices to Engineered Hearts: A Clinician's Guide to 3D Printing and Bioprinting.","authors":"Alisa Morss Clyne, Elazer R Edelman","doi":"10.1161/CIRCULATIONAHA.126.081751","DOIUrl":"10.1161/CIRCULATIONAHA.126.081751","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"154 18","pages":"1867-1875"},"PeriodicalIF":41.3,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13729883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-11-03Epub Date: 2026-09-08DOI: 10.1161/CIRCULATIONAHA.126.080527
Mustafa Yalcinkaya, Cheng-Chieh Hsu, Linke Li, Ranran Wang, David Ngai, Pablo Sánchez Vela, Ines Fernandez-Maestre, Malgorzata Olszewska, Wenli Liu, Miao Chen, Sandra Schiavone, Tong Xiao, Eirini P Papapetrou, Nan Wang, Ross Levine, Zhi Yu, Ira Tabas, Alan R Tall
{"title":"Impaired Glycolysis Leads to Defective Efferocytosis and Impaired Plaque Resolution in <i>Tet2</i> Clonal Hematopoiesis.","authors":"Mustafa Yalcinkaya, Cheng-Chieh Hsu, Linke Li, Ranran Wang, David Ngai, Pablo Sánchez Vela, Ines Fernandez-Maestre, Malgorzata Olszewska, Wenli Liu, Miao Chen, Sandra Schiavone, Tong Xiao, Eirini P Papapetrou, Nan Wang, Ross Levine, Zhi Yu, Ira Tabas, Alan R Tall","doi":"10.1161/CIRCULATIONAHA.126.080527","DOIUrl":"10.1161/CIRCULATIONAHA.126.080527","url":null,"abstract":"<p><strong>Background: </strong>Clonal hematopoiesis (CH) arising from mutations in hematopoietic genes has been identified as an important risk factor for atherosclerotic cardiovascular disease. Despite the established role of some CH mutations in promoting atherosclerosis progression, their role in clinically relevant LDL (low-density lipoprotein) lowering-induced plaque remodeling or regression has not been extensively studied.</p><p><strong>Methods: </strong>To assess the effects of TET2 (tet methylcytosine dioxygenase 2) CH on plaque resolution, we prepared control or chimeric <i>Tet2</i><sup><i>+/</i>-</sup> CH mice with conditional deletion of <i>Tet2</i> in hematopoietic stem cells during LDL lowering-induced plaque remodeling. After establishing atherosclerosis by Western diet feeding for 12 weeks in <i>Ldlr</i><sup><i>-/</i>-</sup> mice, <i>Tet2</i> was deleted by tamoxifen injection, and hypercholesterolemia was either normalized to simulate clinical lipid management, or mice were continued on the Western diet.</p><p><strong>Results: </strong>Unlike control mice, <i>Tet2</i><sup><i>+/</i>-</sup> CH mice failed to significantly reduce necrotic core area or increase fibrous cap thickness and showed impaired macrophage efferocytosis during LDL lowering. Single-cell RNA sequencing and gene set enrichment analysis of aortic cell populations revealed that <i>Tet2</i> deficient monocyte/macrophage populations were defective in glycolysis, phagocytosis, and actin polymerization. <i>Tet2</i>-deficient bone marrow-derived macrophages and <i>Tet2</i><sup><i>+/</i>-</sup> induced pluripotent stem cell-derived human macrophages showed defective ability to sustain continuing rounds of efferocytosis. Bone marrow-derived macrophages displayed reduced apoptotic cell binding and internalization and impaired activity of Wiskott-Aldrich syndrome protein and SCAR (suppressor of cyclic AMP receptor) homolog complex mediated actin polymerization. We linked these defects to reduced anaerobic glycolysis and lactate levels and rescued them by lactate supplementation or by treatment with the HIF-1α (hypoxia-inducible factor 1α) activator molidustat. Molidustat treatment reversed the defects in necrotic core and fibrous cap formation during LDL lowering-induced plaque remodeling in <i>Tet2</i><sup><i>+/</i>-</sup> CH mice. Reduced plasma lactate levels were also shown in TET2 clonal hematopoiesis of indeterminate potential carriers in the UK Biobank.</p><p><strong>Conclusions: </strong>Our data identify impaired efferocytosis and glycolysis-lactate-actin polymerization pathways in advanced atherosclerosis as potential therapeutic targets to induce proresolving restructuring of the plaque immune cells and to promote beneficial atherosclerosis remodeling in subjects with <i>TET2</i> CH.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"1829-1847"},"PeriodicalIF":41.3,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13556357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Targeting ALDOA Lactylation Reverses Vascular Remodeling in Pulmonary Hypertension by Disrupting Actin Polymerization and YAP Activation.","authors":"Xiaoxun Huang, Jincheng Zhang, Qingye Zeng, Minghui Lin, June Bai, Huazhuo Feng, Jing Liu, Zhao Sha, Tongyu Peng, Yicheng Lv, Xiaoyu Zhang, Shengli Li, Tongqi Li, Jin Qu, Shuai Shao, Qian Liu, Shuxin Liang, Kai Yang, Haiyang Tang, Zhu Zhang, Yuhu He, Zhenzhen Duan, Deping Kong","doi":"10.1161/CIRCULATIONAHA.125.078300","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.125.078300","url":null,"abstract":"<p><strong>Background: </strong>Maladaptive vascular remodeling is a hallmark of pulmonary hypertension (PH), and therapeutic strategies directly targeting the pathological activity of smooth muscle cells remain limited. Metabolic and epigenetic dysregulation are established drivers of PH, and lysine lactylation has emerged as a novel posttranslational modification implicated in diverse diseases; however, its direct contribution to PH progression remains undefined.</p><p><strong>Methods: </strong>Integrated lactylomic and proteomic profiling was performed in hypoxic human pulmonary arterial smooth muscle cells. The functional role of ALDOA (aldolase A) lactylation at lysine 42 (K42) was assessed using site-specific mutant virus and smooth muscle cell-specific inducible ALDOA knockout mice in 2 established PH models: SU5416+hypoxia in mice and monocrotaline in rats.</p><p><strong>Results: </strong>We identified ALDOA as a prominent lactylation target in hypoxic pulmonary arterial smooth muscle cells, with K42 lactylation consistently elevated in primary pulmonary arterial smooth muscle cells derived from PH rodent models and human PH tissues. Mechanistically, AARS1 (alanyl-tRNA synthetase 1)-mediated ALDOA K42 lactylation enhanced its binding to γ-actin, independent of glycolytic activity. This lactylation-enhanced interaction promoted F-actin polymerization and activated YAP (Yes-associated protein) signaling via LATS1 (large tumor suppressor kinase 1) inhibition, thereby driving pulmonary arterial smooth muscle cell proliferation and phenotypic switching. Moreover, YAP/TEAD4 (TEA domain transcription factor 4)-mediated transcriptional upregulation of AARS1 established a positive feedback loop reinforcing ALDOA K42 lactylation under hypoxia. In vivo, ALDOA inducible knockout or reconstitution with the lactylation-deficient K42R (lysine 42 mutant to arginine) mutant attenuated experimental PH progression, with suppressed F-actin/YAP activation and reduced vascular remodeling. Furthermore, competitive inhibition of lactylation through β‑alanine reduced ALDOA K42 lactylation and ameliorated vascular remodeling in ALDOA-overexpressing rodent PH models. Translationally, pharmacological disruption of the ALDOA/γ-actin interaction by raltegravir suppressed cytoskeletal reorganization and YAP signaling, mitigating PH progression in both mouse and rat models.</p><p><strong>Conclusions: </strong>AARS1-mediated ALDOA K42 lactylation drives pulmonary vascular remodeling through a mechanism independent of ALDOA's catalytic activity, promoting F-actin polymerization and YAP activation. Precision targeting of this modification selectively inhibits pathological signaling while preserving metabolic homeostasis, highlighting a translational potential for precision intervention in PH.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-11-03Epub Date: 2026-09-08DOI: 10.1161/CIRCULATIONAHA.126.080483
Marie de Bakker, Alexander J F Thurston, Ola Hammarsten, Mareta Khachatryan, Takeshi Fujisawa, Ziwen Li, John W McEvoy, Bertil Lindahl, Torbjørn Omland, Naveed Sattar, Cathie L M Sudlow, Kai M Eggers, Paul Welsh, Nicholas L Mills
{"title":"Macrotroponin Complexes and Risk of Cardiovascular Events.","authors":"Marie de Bakker, Alexander J F Thurston, Ola Hammarsten, Mareta Khachatryan, Takeshi Fujisawa, Ziwen Li, John W McEvoy, Bertil Lindahl, Torbjørn Omland, Naveed Sattar, Cathie L M Sudlow, Kai M Eggers, Paul Welsh, Nicholas L Mills","doi":"10.1161/CIRCULATIONAHA.126.080483","DOIUrl":"10.1161/CIRCULATIONAHA.126.080483","url":null,"abstract":"<p><strong>Background: </strong>Cardiac troponin is increasingly used for cardiovascular risk prediction. While abnormal values often reflect subclinical cardiovascular disease, they can be raised due to interference, where antibodies influence the assay or clearance of troponin from the circulation by forming macrotroponin complexes. The frequency of macrotroponins and its association with future risk are unknown.</p><p><strong>Methods: </strong>In a general population cohort, participants with both cardiac troponin I and T measurements available (n=19 499, median 49 [25th-75th percentile, 36-58] years of age, 58.3% women) were categorized into 3 groups: no myocardial injury (neither cardiac troponin I or T was elevated), suspected macrotroponin (either cardiac troponin was elevated and discordant with a >3-fold difference in concentration), and myocardial injury (either cardiac troponin was elevated without discordance). Macrotroponin complex formation was verified in a subset of samples (n=203) using immunoglobulin depletion and ultracentrifugation. Associations with future myocardial infarction, ischemic stroke, or cardiovascular death were evaluated using Cox proportional hazards models adjusted for known cardiovascular risk factors. The generalizability of our findings was determined through replication in a second general population cohort study.</p><p><strong>Results: </strong>Elevated cardiac troponin I was present in 1% (193 of 19 499) of participants and elevated cardiac troponin T in 6% (1159 of 19 499). Among those, 48% and 57% were discordant, respectively. Biochemical testing attributed 92.5% of discordant troponin I and 15.4% of discordant troponin T to macrotroponin complexes. Participants with myocardial injury were at increased risk of future cardiovascular events compared with those without (cardiac troponin I: adjusted hazard ratio [HR], 2.90 [95% CI, 1.99-4.22]; cardiac troponin T: adjusted HR, 1.99 [95% CI, 1.63-2.42]), whereas those with suspected macrotroponin had similar risk as those without elevated values for suspected macrotroponin I (adjusted HR, 1.59 [95% CI, 0.94-2.70]) and T (adjusted HR, 1.27 [95% CI, 1.00-1.61]). Findings were similar in the replication cohort.</p><p><strong>Conclusions: </strong>Assay interference due to macrotroponin complex formation is common in individuals with elevated cardiac troponin concentrations in the general population, particularly for cardiac troponin I. This has important implications for the use of cardiac troponin testing for cardiovascular risk assessment in the general population.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"1777-1790"},"PeriodicalIF":41.3,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13722435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-11-02DOI: 10.1161/CIRCULATIONAHA.126.083383
Louisa A Mounsey, Dongyu Wang, Pedro H Ribeiro, Sophie M Nemeth, Juhi K Parekh, Jordan B Strom, Chiadi Ndumele, Norrina B Allen, Bruce Psaty, Jorge R Kizer, Daniel Levy, Rudolf A de Boer, Mahnaz Maddah, Shaan Khurshid, Patrick T Ellinor, Emily S Lau, Jonathan Cunningham, Sadiya S Khan, Jennifer E Ho
{"title":"Performance of the PREVENT-HF Equations Across Heart Failure Subtypes in Community-Based and Ambulatory Healthcare Samples.","authors":"Louisa A Mounsey, Dongyu Wang, Pedro H Ribeiro, Sophie M Nemeth, Juhi K Parekh, Jordan B Strom, Chiadi Ndumele, Norrina B Allen, Bruce Psaty, Jorge R Kizer, Daniel Levy, Rudolf A de Boer, Mahnaz Maddah, Shaan Khurshid, Patrick T Ellinor, Emily S Lau, Jonathan Cunningham, Sadiya S Khan, Jennifer E Ho","doi":"10.1161/CIRCULATIONAHA.126.083383","DOIUrl":"10.1161/CIRCULATIONAHA.126.083383","url":null,"abstract":"<p><strong>Background: </strong>The PREVENT-HF equations estimate 10-year risk of overall heart failure (HF), inclusive of both HF with preserved and reduced ejection fraction (HFpEF; HFrEF). Given differential risk factor profiles, pathophysiology, and therapeutic strategies for each HF subtype, we sought to examine the performance of PREVENT-HF for subtype-specific risk assessment.</p><p><strong>Methods: </strong>We included data from five pooled longitudinal cohort studies (baseline exam 1989 to 2013) and two longitudinal primary-care electronic health record-based samples (Beth Israel Deaconess Medical Center [BIDMC], baseline 2004 to 2014; Mass General Brigham [MGB], baseline 2001 to 2018). We assessed the performance of the PREVENT-HF equations in predicting 10-year incident HFrEF and HFpEF, including model discrimination (area under the receiver operating characteristic curve [AUROC]; average precision [AP]/event rate) and calibration (integrated calibration index [ICI]), in adults aged 30-79 years without prevalent cardiovascular disease or HF.</p><p><strong>Results: </strong>The pooled cohort studies included 23,652 (55% women, age 60 ± 13 years), of whom 1,232 developed HF (432 [35%] HFpEF, 522 [42%] HFrEF). The BIDMC sample included 29,815 (55% women, 50 ± 13 years), of whom 259 (1%) developed HF (133 [51%] HFpEF, 101 [39%] HFrEF). MGB included 138,999 (62% women, 52 ± 13 years), of whom 1050 developed HF (586 [56%] HFpEF, 381 [36%] HFrEF). PREVENT-HF demonstrated better discrimination for HFpEF than HFrEF across all samples: in the pooled cohorts, the AUROC for HFpEF was 0.824 (95% CI 0.807, 0.839) versus 0.789 (95% CI 0.770, 0.807) for HFrEF; in BIDMC, the AUROC for HFpEF was 0.897 (95% CI 0.874, 0.918) versus 0.833 (95% CI 0.791, 0.869) for HFrEF; in MGB, the AUROC for HFpEF was 0.864 (95% CI 0.848, 0.880) versus 0.797 (95% CI 0.771, 0.820) for HFrEF. Similar results were reflected in the AP/event rate ratios: 2.92 (95% CI 2.47, 3.54) for HFpEF compared to 2.66 (95% CI 2.33, 3.14) for HFrEF in the pooled cohorts; 8.08 (95% CI 6.12, 12.30) for HFpEF compared to 5.12 (95% CI 3.84, 8.17) for HFrEF in BIDMC; and 6.84 (95% CI 5.66, 8.28) for HFpEF compared to 4.12 (95% CI 3.37, 5.16) for HFrEF in MGB. Calibration was similar for HFpEF and HFrEF across samples. For example, in the pooled cohorts, the ICI for HFpEF was 0.041 (95% CI 0.039, 0.043) and for HFrEF was 0.038 (95% CI 0.036, 0.040).</p><p><strong>Conclusions: </strong>PREVENT-HF demonstrated excellent discrimination for both HF subtypes across community-based cohorts and real-world samples, with consistently better discrimination for HFpEF as compared to HFrEF. Given PREVENT-HF was developed to estimate overall HF risk rather than subtype-specific risk, future studies are needed to establish subtype-specific risk thresholds.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-11-02DOI: 10.1161/CIRCULATIONAHA.126.083153
Maximilian J Schloss, Melissa Young, Elizabeth A Barrett, Eileen M Stock, Ellen M DeMatt, Biswas Kousick, Elaine E Tseng, Deepak L Bhatt, Faisal G Bakaeen, Ryan E Ferguson, J Michael Gaziano, Marco A Zenati
{"title":"Long-Term Outcomes of Endoscopic or Open Vein Harvesting for Coronary Artery Bypass Grafting: A 10-Year Follow-Up of the REGROUP Randomized Clinical Trial.","authors":"Maximilian J Schloss, Melissa Young, Elizabeth A Barrett, Eileen M Stock, Ellen M DeMatt, Biswas Kousick, Elaine E Tseng, Deepak L Bhatt, Faisal G Bakaeen, Ryan E Ferguson, J Michael Gaziano, Marco A Zenati","doi":"10.1161/CIRCULATIONAHA.126.083153","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.083153","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-11-02DOI: 10.1161/CIRCULATIONAHA.126.081422
Rebecca L Tisdale, Neil M Kalwani, Jun Fan, Valerie McDonald, Evan F Shalen, Brian Chan, Aradhana Verma, Natasha Din, Anju Sahay, Andrew P Ambrosy, Paul Heidenreich, Alexander T Sandhu
{"title":"Validation of the PREVENT-HF Risk Prediction Equation in US Veterans.","authors":"Rebecca L Tisdale, Neil M Kalwani, Jun Fan, Valerie McDonald, Evan F Shalen, Brian Chan, Aradhana Verma, Natasha Din, Anju Sahay, Andrew P Ambrosy, Paul Heidenreich, Alexander T Sandhu","doi":"10.1161/CIRCULATIONAHA.126.081422","DOIUrl":"10.1161/CIRCULATIONAHA.126.081422","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13729808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-10-31DOI: 10.1161/CIRCULATIONAHA.126.082827
Xiao-Fei Gao, Yan Wang, Hong Jiang, Bo Li, Yi-Bing Shao, Jun Luo, Fa-Xin Ren, Fan Ouyang, Zhi-Kui Chen, Hai-Tao Yuan, Cheng Wang, Bing Han, Ping-Xi Xiao, Yi-Qiang Yuan, Zhen-Wen Yang, Liu Miao, Xiang Ma, Jian Yang, Dong-Fang You, Shao-Liang Chen, Jun-Jie Zhang
{"title":"Transcatheter Aortic Valve Replacement in Pure Aortic Regurgitation: The Randomized SEASON-AR Clinical Trial.","authors":"Xiao-Fei Gao, Yan Wang, Hong Jiang, Bo Li, Yi-Bing Shao, Jun Luo, Fa-Xin Ren, Fan Ouyang, Zhi-Kui Chen, Hai-Tao Yuan, Cheng Wang, Bing Han, Ping-Xi Xiao, Yi-Qiang Yuan, Zhen-Wen Yang, Liu Miao, Xiang Ma, Jian Yang, Dong-Fang You, Shao-Liang Chen, Jun-Jie Zhang","doi":"10.1161/CIRCULATIONAHA.126.082827","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.082827","url":null,"abstract":"<p><strong>Background: </strong>For patients with severe pure aortic regurgitation (AR) at high surgical risk, guideline-directed medical therapy (GDMT) is often the only available option. Transfemoral transcatheter aortic valve replacement (TAVR) is an established treatment for aortic stenosis and has also been evaluated in patients with pure AR. However, no adequately powered randomized trial has compared TAVR with GDMT alone in this population.</p><p><strong>Methods: </strong>We conducted a prospective, investigator-initiated, multicenter, randomized, open-label trial in China. Patients with severe pure AR for whom surgery was considered difficult or unacceptable by the local heart team or who persistently declined surgery were randomly assigned at a 1:1 ratio to receive transfemoral TAVR with the VitaFlow system plus GDMT or GDMT alone. The primary end point was a composite of all-cause death, disabling stroke, or heart failure rehospitalization at 1 year.</p><p><strong>Results: </strong>We assigned 210 patients with severe pure AR to the TAVR group (n=109) or GDMT group (n=101) at 18 centers. At 1-year follow-up, the Kaplan-Meier estimate of the primary end point was significantly lower in the TAVR group than in the GDMT group (8.3% vs 24.8%; hazard ration [HR], 0.31 [95% CI, 0.14-0.66]; <i>P</i>=0.001), driven primarily by a reduction in heart failure rehospitalization (3.7% vs 21.3%; HR, 0.16 [95% CI, 0.06-0.47]; <i>P</i> < 0.001). TAVR was associated with higher rates of major or life-threatening bleeding and new permanent pacemaker implantation, most of which occurred within 30 days after the procedure.</p><p><strong>Conclusions: </strong>Among patients with severe pure AR, TAVR plus GDMT significantly reduced the rate of all-cause death, disabling stroke, or heart failure rehospitalization at 1 year compared with GDMT alone despite higher 30-day rates of major or life-threatening bleeding and new permanent pacemaker implantation.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifier: NCT04864145.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-10-27Epub Date: 2026-10-26DOI: 10.1161/CIR.0000000000001489
Tzu-Pin Shentu, Tong Wu, Zhengjie Zhou, Jin Li, Chih-Fan Yeh, Jiayu Zhu, Ru-Ting Huang, Bernadette A Miao, Brian Xi, Jason Lo, Lauryn Carver, Tzu-Han Lee, Lisheng Zhang, Devin Harrison, Chani J Hodonsky, Gaelle Auguste, Uma Thanigai Arasu, Minna U Kaikkonen, Aliya N Husain, Matthew V Tirrell, Clint L Miller, Bryan C Dickinson, Kai-Chien Yang, Yun Fang
{"title":"Correction to: Mechanosensitive Endothelial METTL7A Regulates Internal m<sup>7</sup>G mRNA Methylation and Protects Against Atherosclerosis.","authors":"Tzu-Pin Shentu, Tong Wu, Zhengjie Zhou, Jin Li, Chih-Fan Yeh, Jiayu Zhu, Ru-Ting Huang, Bernadette A Miao, Brian Xi, Jason Lo, Lauryn Carver, Tzu-Han Lee, Lisheng Zhang, Devin Harrison, Chani J Hodonsky, Gaelle Auguste, Uma Thanigai Arasu, Minna U Kaikkonen, Aliya N Husain, Matthew V Tirrell, Clint L Miller, Bryan C Dickinson, Kai-Chien Yang, Yun Fang","doi":"10.1161/CIR.0000000000001489","DOIUrl":"https://doi.org/10.1161/CIR.0000000000001489","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"154 17","pages":"e664"},"PeriodicalIF":41.3,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-10-27Epub Date: 2026-08-28DOI: 10.1161/CIRCULATIONAHA.126.082639
John W Davis, JoAnn E Manson
{"title":"Cholecalciferol and Menaquinone Supplementation: Does Prevention of Coronary Artery Calcium Progression Mean Heart Benefit?","authors":"John W Davis, JoAnn E Manson","doi":"10.1161/CIRCULATIONAHA.126.082639","DOIUrl":"10.1161/CIRCULATIONAHA.126.082639","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"1666-1668"},"PeriodicalIF":41.3,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}